Tolliver Kei S 4
4 · Sucampo Pharmaceuticals, Inc. · Filed May 30, 2013
Insider Transaction Report
Form 4
Tolliver Kei S
Director
Transactions
- Award
Director Stock Option (Right to Buy)
2013-05-22+30,000→ 30,000 totalExercise: $8.62Exp: 2023-05-22→ Class A Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The options vest in twelve equal quarterly installments.